ESR1 and breast cancer: We then tested the impact of reducing each of these kinases on ERα levels in the aforementioned BC cell lines and found that the reduction of receptor levels caused by cell treatment with esiRNA directed against these kinases was predominant in invasive ductal carcinoma (IDC) cells compared to not-IDC cells.